Eli Lilly and Company (LLY)
734.97 USD -20.94 (-2.77%) Volume: 4.58M
Eli Lilly and Company’s stock price currently stands at 734.97 USD, experiencing a decrease of -2.77% this trading session with a trading volume of 4.58M, yet showcasing a positive Year-to-Date (YTD) performance with a rise of +26.08%, reflecting the company’s robust market position and growth potential.
Latest developments on Eli Lilly and Company
Key events driving Eli Lilly & Co’s stock price include a surge in demand for weight-loss drugs, leading to an unprecedented situation for the company’s CFOs. This demand has prompted Eli Lilly to raise its 2024 sales forecast by $2 billion. The company’s Q1 2024 net income also reported a significant 67% increase, further bolstering the stock. However, competition is heating up with Novo Nordisk, putting pressure on pricing. Despite this, analysts remain positive about Eli Lilly’s prospects, revealing optimistic stock price targets after earnings.
A look at Eli Lilly and Company Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Eli Lilly & Company seems to have a positive long-term outlook. With a high momentum score of 5, the company is showing strong performance and growth potential. Additionally, the growth score of 3 suggests that Eli Lilly & is positioned well for future expansion and development. While the value, dividend, and resilience scores are not as high, the overall outlook for the company appears to be promising.
Eli Lilly & Company is a pharmaceutical company that discovers, develops, manufactures, and sells a variety of products for both humans and animals. With a focus on neuroscience, endocrine, anti-infectives, cardiovascular agents, oncology, and animal health products, the company has a diverse portfolio that is sold globally. The Smartkarma Smart Scores indicate that Eli Lilly & has strong momentum and growth potential, which bodes well for its future success in the pharmaceutical industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
